naltrexone implant (OLANI) / Go Medical - LARVOL DELTA

NCI protocol 10250: A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma (clinicaltrials.gov) - P2 | N=23 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Nov 2026

Trial completion date • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • Uterine Leiomyosarcoma • SLFN • SLFN11

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Nov 2025 ➔ Nov 2026

Platinum resistant • Trial completion date • Trial primary completion date • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA • HRD

SWOG S2001: Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • BRCA • BRCA1

SWOG S2001: Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (clinicaltrials.gov) - P2 | N=88 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • BRCA • BRCA1

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (clinicaltrials.gov) - P1 | N=13 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Oncology • Solid Tumor • BRCA1 • BRCA2 • BRIP1 • CD4 • FANCA

NCI10217: Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Sep 2026

Biomarker • Trial completion date • Oncology • Solid Tumor • BARD1 • BRCA1 • BRCA2 • BRIP1 • CD4 • FANCA • NBN • PIK3CA • RAD51 • RAD51B • RAD51C • RAD51D

NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P3 | N=579 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2026

Platinum sensitive • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

NCI-2016-01130: Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer (clinicaltrials.gov) - P2 | N=81 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • HER-2

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P1/2 | N=51 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Trial completion • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jun 2026

Platinum resistant • Trial completion date • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • Urothelial Cancer • BRCA1 • BRCA2 • PD-L1

Pediatric Collagenous Gastritis: Case Series Highlighting Clinical, Endoscopic, and Pathologic Insight Into a Rare Disease in Hawaii's Multiethnic Population (CAP 2025) - "Design: We report a series of pediatric CG cases from 5 patients who had biopsies and were treated at Kapi'olani Medical Center, Honolulu from 2019–2024... Our cohort showed diverse stool patterns, emesis, abdominal pain, weight loss, and iron deficiency anemia, consistent with other studies. Unlike previous studies on pediatric CG that reported to predominantly affect females and was linked to autoimmune diseases, our cohort consisted primarily of males without autoimmune conditions. Notably, despite symptom resolution, follow-up biopsies showed persistent histologic CG."

Clinical • Anemia • Celiac Disease • Constipation • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Bowel Disease • Pediatrics • Rare Diseases

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2026

Platinum resistant • Platinum sensitive • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2028 ➔ Jul 2026

Trial completion date • Oncology • Pancreatic Cancer • Solid Tumor • CD4

COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - P2/3 | N=582 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2025 ➔ Jul 2026

Platinum resistant • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • MUC16

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Sep 2025 ➔ Jul 2026

Trial primary completion date • Oncology • Pancreatic Cancer • Solid Tumor • CD4

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2028

Trial completion date • Oncology • Pancreatic Cancer • Solid Tumor • CD4

Racial/Ethnic Differences in Gestational Diabetes and Its Association with Maternal and Neonatal Outcomes among Women in Hawai'i. (PubMed, Matern Child Health J) - "Prevalence of GDM in hospitalized deliveries in Hawai'i's multi-ethnic population of women has increased nearly 2-fold in the last two decades. All Asian Americans remain at highest risk despite lower maternal BMI at delivery. NH women are younger yet have similar frequency of co-morbidities and comprise the largest proportion of GDM cases overall."

Journal • Diabetes • Gestational Diabetes • Metabolic Disorders

Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons (clinicaltrials.gov) - P2 | N=250 | Not yet recruiting | Sponsor: Go Medical Industries Pty Ltd | Trial completion date: Mar 2028 ➔ Jan 2029 | Trial primary completion date: Mar 2027 ➔ Jan 2028

Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol) • Substance Abuse

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=50 ➔ 24 | Trial completion date: Mar 2026 ➔ Jul 2026 | Trial primary completion date: Mar 2026 ➔ Mar 2025

Enrollment change • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • IDH1 • IDH2

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations (clinicaltrials.gov) - P2 | N=89 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=145 ➔ 89 | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Apr 2025

Enrollment change • Trial completion date • Trial primary completion date • Anaplastic Astrocytoma • Biliary Cancer • Brain Cancer • Cholangiocarcinoma • Glioblastoma • Glioma • Oncology • Solid Tumor • IDH1 • IDH2

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Neuroendocrine Tumor • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: OHSU Knight Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Sarcoma • Solid Tumor

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: OHSU Knight Cancer Institute | Initiation date: Mar 2025 ➔ Jun 2025

Trial initiation date • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Sarcoma • Solid Tumor

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - P1 | N=55 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2026

Platinum resistant • Trial completion date • Trial primary completion date • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD4